6-K filed Jul 30, 2026 at 07:34 ET
Sanofi reported H1 2026 net sales of €22,106M (+11.1% reported, +15.7% CER), driven by Dupixent (+34.4% CER) and new launches. Business EPS rose 17.1% to €3.97, and guidance was raised to ~10% CER sales growth for FY2026, with Business EPS growing slightly faster. However, IFRS net income fell 66.3% to €1,957M, largely due to a €1,031M impairment (€952M for discontinued amlitelimab) and the prior-year Opella divestiture gain. The underlying business performance is strong, but the pipeline setback and elevated restructuring costs temper the outlook.